Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: An open-label study

References

• Ananth J. Treatment-resistant depression. Psychother. Psychosom. 1998; 67: 61–70
   Google Scholar
• Ballenger JC. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry 1988; 49(Suppl)13–21
   PubMedGoogle Scholar
• Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782–790
   PubMed Web of Science ®Google Scholar
• Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 2002; 63: 737–741
   PubMed Web of Science ®Google Scholar
• Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003; 64: 403–407
   PubMed Web of Science ®Google Scholar
• Bauer M. The combined use of lithium and SSRIs. J Serotonin Res 1995; 2: 69–76
   Google Scholar
• Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5–43
   PubMedGoogle Scholar
• Bauer M, Adli M, Baethge C, Berghofer A, Sasse J, Heinz A, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003a; 48: 440–448
   PubMedGoogle Scholar
• Bauer M, Forsthoff A, Baethge C, Adli M, Berghofer A, Dopfmer S, et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2003b; 253: 132–139
   PubMed Web of Science ®Google Scholar
• Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307–314
   PubMed Web of Science ®Google Scholar
• Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord 2005; 84: 117–125
   PubMed Web of Science ®Google Scholar
• Brosen K, Kragh-Sorensen P. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 1993; 15: 258–260
   PubMedGoogle Scholar
• Bruijn JA, Moleman P, Mulder PG, van den Broek WW. Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry 1998; 59: 657–663
   PubMedGoogle Scholar
• Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12: 2985–2992
   PubMed Web of Science ®Google Scholar
• Bschor T, Adli M, Baethge C, Eichmann U, Ising M, Uhr M, et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 2002; 27: 470–478
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 1992; 12: S53–S56
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck PE, Jr, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 1999a; 156: 1019–1023
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999b; 60: 79–88
   PubMed Web of Science ®Google Scholar
• Ciusani E, Zullino DF, Eap CB, Brawand-Amey M, Brocard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol 2004; 18: 559–566
   PubMed Web of Science ®Google Scholar
• Coryell W. Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled studies. Ann Clin Psychiatry 2000; 12: 141–146
   PubMedGoogle Scholar
• Cowen PJ, McCance SL, Ware CJ, Cohen PR, Chalmers JS, Julier DL. Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 1991; 159: 341–346
   PubMedGoogle Scholar
• Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, et al. Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry 1991; 52: 472–476
   PubMed Web of Science ®Google Scholar
• Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 1996; 32: 647–652
   PubMed Web of Science ®Google Scholar
• Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259–266
   PubMed Web of Science ®Google Scholar
• De la Fuente JM, Mendlewicz J. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. Biol Psychiatry 1992; 32: 369–374
   PubMedGoogle Scholar
• De Montigny C. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol 1994; 9(Suppl 2)31–35
   PubMedGoogle Scholar
• De Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252–256
   PubMed Web of Science ®Google Scholar
• DeBattista C. Augmentation and combination strategies for depression. J Psychopharmacol 2006; 20: 11–18
   PubMedGoogle Scholar
• DeVeaugh-Geiss, J, Ascher, J, Brook, S, Cedrone, J, Earl, N, Emsley, R, , et al. 2000. Safety and tolerability of lamotrigine in controlled monotherapy trials in mood disorders. Presented at the 39th Annual ACNP Meeting, December 10–14, San Juan, Puerto Rico.
   Google Scholar
• Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998; 59(Suppl 5)51–58
   PubMed Web of Science ®Google Scholar
• Eap CB, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther Drug Monit 1999; 21: 166–170
   PubMed Web of Science ®Google Scholar
• Ebes, F, Van Lookeren-Campagne, AM, Hartmans, HLA. 1998. A phase I, single center, single-blind, placebo-controlled multiple dose study of the interaction between Org 3770 and carbamazepine in healthy male volunteers. Study 22514, Report No. NL 0003854, Oss: N. V. Organon (Data on file).
   Google Scholar
• Elphick M. Clinical issues in the use of carbamazepine in psychiatry: a review. Psychol Med 1989; 19: 591–604
   PubMed Web of Science ®Google Scholar
• Feiner NF. Antiepileptic drug augmentation for treatment-resistant depression. J Clin Psychiatry 1997; 58: 361–363
   PubMedGoogle Scholar
• Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 1997; 58: 271–273
   PubMedGoogle Scholar
• Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006; 119: 478–481
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–614
   PubMed Web of Science ®Google Scholar
• Gabriel A. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress. Anxiety 2006; 23: 485–488
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Himmelhoch JM, Detre T, Kupfer DJ, Swartzburg M, Byck R. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis 1972; 155: 216–220
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 1997; 277: 333–340
   PubMed Web of Science ®Google Scholar
• Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995; 166: 80–86
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59(Suppl 6)74–81
   PubMedGoogle Scholar
• Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999; 19: 511–532
   PubMed Web of Science ®Google Scholar
• Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 2000; 61: 526–527
   PubMedGoogle Scholar
• Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 1997; 72: 145–148
   PubMed Web of Science ®Google Scholar
• Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, et al. Carbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol 2000; 20: 46–53
   PubMed Web of Science ®Google Scholar
• Laurenza A, Asnis G, Beaman M. A double-blind placebo-controlled study supporting the efficacy of lamotrigine in unipolar depression. Bipolar Disord 1999; 1: 39–40
   Google Scholar
• Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996; 29: 156–158
   PubMed Web of Science ®Google Scholar
• Londborg, PD, Cutler, NR, Cunningham, LA, Haines, FX, Pahl, JJ, West, SA. 1999. A double-blind, placebo-controlled study suuporting the efficacy of lamotrigine in unipolar depression. Poster presented at the American Psychiatric Association Annual Meeting, May 15–20, Washington, DC. (SCAA2011 [613]).
   Google Scholar
• Maltese TM. Adjunctive lamotrigine treatment for major depression. Am J Psychiatry 1999; 156: 1833
   PubMed Web of Science ®Google Scholar
• Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 1993; 36: 615–616
   PubMedGoogle Scholar
• McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 2002; 4: 207–213
   PubMed Web of Science ®Google Scholar
• Mendels J. Lithium in the treatment of depression. Am J Psychiatry 1976; 133: 373–378
   PubMed Web of Science ®Google Scholar
• Moustgaard G. Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium. J Clin Psychopharmacol 2000; 20: 268
   PubMedGoogle Scholar
• Nelson JC, Mazure CM. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986; 143: 363–366
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 2000; 61(Supp 13)19–25
   PubMedGoogle Scholar
• Nemets B, Bersudsky Y, Belmaker RH. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J Clin Psychiatry 2005; 66: 586–590
   PubMed Web of Science ®Google Scholar
• Neumann, J, Seidel, K, Wunderlich, H. 1984. Comparative studies of the effect of carbamazepine and trimipramine in depression. Emrich, HM, Okuma, T, Muller, AA. Anticonvulsants in affective disorders Elsevier, Amsterdamthe Netherlands, 160–166.
   Google Scholar
• Nickel C, Lahmann C, Tritt K, Muehlbacher M, Kaplan P, Kettler C, et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord 2005; 87: 243–252
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990; 51(Suppl)39–47
   PubMedGoogle Scholar
• Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 2002; 63: 337–344
   PubMed Web of Science ®Google Scholar
• O'Flanagan PM. Letter: Clomipramine infusion and lithium carbonate: a synergistic effect?. Lancet 1973; 2: 974
   PubMedGoogle Scholar
• Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347–356
   PubMed Web of Science ®Google Scholar
• Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29–34
   PubMed Web of Science ®Google Scholar
• Prasad AJ. Efficacy of carbamazepine as an antidepressant in chronic resistant depressives. J Indian Med Assoc 1985; 83: 235–237
   PubMedGoogle Scholar
• Rocha FL, Hara C. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 2003; 18: 97–99
   PubMed Web of Science ®Google Scholar
• Rouillon F, Gorwood P. The use of lithium to augment antidepressant medication. J Clin Psychiatry 1998; 59(Suppl 5)32–39
   PubMedGoogle Scholar
• Rybakowski J, Matkowski K. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. Eur Neuropsychopharmacol 1992; 2: 161–165
   PubMedGoogle Scholar
• Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 1999; 40: 134–139
   PubMed Web of Science ®Google Scholar
• Schaffer CB, Mungas D, Rockwell E. Successful treatment of psychotic depression with carbamazepine. J Clin Psychopharmacol 1985; 5: 233–235
   PubMedGoogle Scholar
• Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol 2007; 22: 179–182
   PubMed Web of Science ®Google Scholar
• Schneier HA, Kahn D. Selective response to carbamazepine in a case of organic mood disorder. J Clin Psychiatry 1990; 51: 485
   PubMedGoogle Scholar
• Schule C, Romeo E, Uzunov DP, et al. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol Psychiatry 2006; 11: 261–272
   PubMed Web of Science ®Google Scholar
• Schule C, Baghai TC, Di Michele F, et al. Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. Psychoneuroendocrinology 2007; 32: 669–680
   PubMedGoogle Scholar
• Sethi, BB, Tiwari, SC. 1984. Carbamazepine in affective disorders. Emrich, HM, Okuma, T, Muller, AA. Anticonvulsants in affective disorders Elsevier, Amsterdamthe Netherlands, 167–176.
   Google Scholar
• Shapira B, Nemets B, Trachtenberg A, Belmaker RH. Phenytoin as an augmentation for SSRI failures: a small controlled study. J Affect Disord 2006; 96: 123–126
   PubMed Web of Science ®Google Scholar
• Sitsen JM, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol 2000; 14: 172–176
   PubMed Web of Science ®Google Scholar
• Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991; 158: 666–675
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15: 247–250
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology (Berl) 1995; 117: 413–416
   PubMed Web of Science ®Google Scholar
• Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185–189
   PubMed Web of Science ®Google Scholar
• Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 2002; 12: 255–260
   PubMed Web of Science ®Google Scholar
• Stormer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28: 1168–1175
   PubMed Web of Science ®Google Scholar
• Suppes T, Brown ES, McElroy SL, Keck PE, Jr, Nolen W, Kupka R, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 1999; 53: 95–98
   PubMed Web of Science ®Google Scholar
• Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461–474
   PubMed Web of Science ®Google Scholar
• Tylee A, Gastpar M, Lepine JP, Mendlewicz J. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999; 14: 139–151
   PubMed Web of Science ®Google Scholar
• Van der Loos, M, Nolen, W. 2006. Lamotrigine as add-on to lithium in bipolar depression. Presented at the Fifth European Stanley Conference on Bipolar Disorder, Barcelona, October 5–7, 2006.
   Google Scholar
• Walden J, Hesslinger B, Van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 1996; 29: 193–195
   PubMed Web of Science ®Google Scholar
• Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67: 207–212
   PubMed Web of Science ®Google Scholar
• Wittchen, HU, Wunderlich, U, Zaudig, M, Fydrich, T. 1997. (Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. [Structured clinical interview for DSM-IV, Axis I, German version]). Hogrefe, Göttingen.
   Google Scholar
• Wunderlich H, Heim H, Wunderlich HP. Carbamazepin (Finlepsin) bei endogenen affektiven Psychosen: eine neue Therapie. Medicamentum 1982a; 60: 2–8
   Google Scholar
• Wunderlich H, Neumann J, Grünes JU. Carbamazepin (Finlepsin) bei manisch-depressiven Erkrankungen. Deutsches Gesundheitswesen 1982b; 37: 1471
   Google Scholar
• Wunderlich HP, Grunes JU, Neumann J, Zahlten W. [Antidepressive therapy with carbamazepine (Finlepsin)]. Schweiz. Arch Neurol Neurochir Psychiatr 1983; 133: 363–371
   PubMedGoogle Scholar
• Yatham LN, Kusumakar V, Parikh SV, Haslam DR, Matte R, Sharma V, et al. Bipolar depression: treatment options. Can. J Psychiatry 1997; 42(Suppl 2)87S–91
   Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar. Disord. 2005; 7(Suppl 3)5–69
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721–739
   PubMed Web of Science ®Google Scholar
• Zall H, Therman PG, Myers JM. Lithium carbonate: a clinical study. Am J Psychiatry 1968; 125: 549–555
   PubMed Web of Science ®Google Scholar
• Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001; 34: 119–127
   PubMed Web of Science ®Google Scholar